Sutureless coronary artery bypass with biologic glued anastomoses: Preliminary in vivo and in vitro results  by Gundry, Steven R. et al.
A s minimally invasive techniques become increasing-ly common in cardiac operations, the limits of the
sutured anastomosis in coronary artery bypass grafting
are becoming clear. Although the sutured anastomosis
on the arrested heart remains the gold standard by
which all other techniques are measured, alternative
methods of anastomosing the internal thoracic artery
(ITA) or saphenous vein to the coronary artery are being
attempted. Various stabilizing devices now permit facile
anastomoses to be performed on the beating heart and
various stapling devices for joining two blood vessels
are now in common use elsewhere in the body.1-4
Despite these advances, truly minimally invasive coro-
Objective: As heart surgery becomes increasingly focused on minimally
invasive techniques, it has become apparent that conventional techniques of
anastomosis will need to be severely altered or abandoned. Toward that end,
we developed and tested in vitro and in vivo coronary artery bypass graft
anastomoses using a biologic glue formulated from bovine albumin and glu-
taraldehyde. We used a double-balloon catheter as a temporary internal stent
to create and seal the anastomosis during gluing.
Methods: Initially, anastomoses were made between cryopreserved human
saphenous vein segments and coronary arteries in vitro on 12 intact bovine
hearts. A total of 42 anastomoses were created with the catheter system
introduced into the distal end of the graft, exiting the back wall, and enter-
ing the anterior wall of the coronary artery. Two balloons (one in the graft
and one in the coronary artery) held the anastomosis stable while the bio-
logic glue was applied externally and allowed to set for 2 minutes. The bal-
loon catheter was then removed from the end of the graft simulating a side-
to-side internal thoracic artery anastomosis. After the graft had been flushed
to assure distal end patency, the open end of the graft was clipped, turning
the anastomosis into an end-to-side graft. A pressure transducer was then
attached to the graft and saline solution forcefully infused.
Results: All grafts easily held a pressure of 300 mm Hg; 10 grafts were test-
ed up to 560 mm Hg without leaks. Distal and proximal coronary artery
patency was checked by examining flow out of the coronary ostia and by cut-
ting arteries distal to the grafts. All anastomoses were patent on being
opened and no glue was seen intraluminally. Subsequently, 3 anastomoses of
the left internal thoracic artery to the left anterior descending artery have
been constructed in goats, with autopsies at 24 hours, 10 months, and 1 year
revealing patent anastomoses.
Conclusion: A biologic glue and catheter system has been developed that
allows a coronary anastomosis with a high bursting strength to be performed.
When the system has been further developed and tested, truly minimally
invasive heart surgery may be possible.  (J Thorac Cardiovasc Surg
2000;120:473-7)
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nary artery bypass must be done through tiny ports
without the use of cardiopulmonary bypass and with
patency rates that must rival those of current or pro-
posed stent technology. An anastomosis constructed
with a biologic or other glue would enable many of
these minimally invasive operations to be performed,
but to date the use of glues in this fashion has been dis-
appointing.5,6 This article describes our use of BioGlue
surgical adhesive (CryoLife, Inc, Marietta, Ga) in both
in vitro construction of coronary artery anastomoses
and the subsequent in vivo application of this technique
in experimental animals.
Materials and methods
BioGlue surgical adhesive is a proprietary compound that
combines glutaraldehyde and concentrated bovine albumin
with distinct properties that make it useful for consideration
as a biologic adhesive for sutureless anastomosis. The com-
pound does not become active until the two agents are mixed
within the applicator tip, but once mixed, a set of approxi-
mately 65% of final holding power is achieved within 20 sec-
onds; full holding power is achieved within 2 minutes. This
occurs regardless of temperature and occurs under water as
well as with air exposure while creating a strong bond. The
glue can be removed by “peeling” it off tissues and instru-
ments. Moreover, the compound appears biologically inert,
with repaired sheep dissections showing the glue to be pre-
sent at least 3 months after use.7 This agent is approved for
use in Europe for the treatment of acute aortic dissection and
for facilitating sutured anastomoses of the carotid artery, but
it remains under investigation in the United States only for
treatment of acute aortic dissection.
To facilitate sutureless coronary artery anastomoses, we
procured 12 bovine hearts from the slaughterhouse and rinsed
the coronary arteries with a saline-heparin solution. Thawed,
previously cryopreserved segments of human saphenous vein
(CryoLife) that were unacceptable for human use were used as
the conduit material. A total of 42 anastomoses were created
with a catheter system that consisted of modified angioplasty
balloon catheters (Ideas for Medicine, St Petersburg, Fla) (Fig
1). In brief, the saphenous vein and left coronary artery to be
bypassed were brought parallel to each other. Incisions were
made on the back of the saphenous vein and the anterior por-
tion of the coronary artery to perform a side-to-side anasto-
mosis. One catheter was introduced into the distal end of the
saphenous vein, brought out through the back wall incision of
the saphenous vein, and placed into the coronary artery to be
bypassed. A second catheter was also introduced into the dis-
tal end of the saphenous vein and was placed within the body
of the saphenous vein adjacent to the anastomosis to maintain
the luminal integrity of the saphenous vein graft. Both bal-
loons were then inflated, so that the two vessels were secured
together. The BioGlue adhesive was applied with its standard
applicator gun and tip and allowed to set for 2 minutes. After
2 minutes, the balloons were deflated and the catheters
removed. The proximal end of the vein graft was fitted with a
standard vein graft cannula (Medtronic/DLP, Grand Rapids,
Mich) and connected to a pressure-transducing box
(Medtronic/DLP). Saline solution was then injected into the
proximal vein graft and flow through the distal end of the vein
graft assured. Once distal flow through the vein graft was
established, the distal end of the graft was clipped with a
medium clip (Ligaclip; Ethicon, Inc, Cincinnati, Ohio). The
vein graft and coronary arteries were then perfused with a
large syringe connected in a Y fashion to the proximal vein
graft and the pressure transducer, and saline solution was
forcefully injected to achieve a pressure of at least 300 mm
Hg. Flow was ascertained through the proximal artery by
observing saline solution coming from the coronary ostia and
from the distal artery by cutting the heart in a bread loaf slice
near the apex of the heart and assessing runoff. Saline solution
continued to be infused forcefully to as high a pressure as
could be achieved competing with the natural runoff through
the coronary arteries.
After in vitro testing, a long-term animal model was
established. Yearling goats weighing approximately 50 kg
were used as the experimental animal. A small left anterior
thoracotomy was performed and the left or right ITA (or
both) was harvested by means of a direct-vision technique.
After a suitable length had been obtained, the artery was
ligated distally and flushed with heparin solution. Through
the same anterior limited thoracotomy, the pericardium was
opened and purse-string sutures were placed on the ascend-
ing aorta and right atrial appendage. Goats were given a 3-
mg/kg dose of sodium heparin and placed on cardiopul-
monary bypass. The ascending aorta was crossclamped and
a single 500-mL dose of Roe crystalloid cardioplegic solu-
tion was administered to produce cardiac arrest. The left
anterior descending (LAD) coronary artery was opened in
its mid portion. Similarly, as described above, the under-
side of the ITA was opened approximately 1 cm from its
distal end. The same modified angioplasty balloon
catheters were then placed into the distal ITA, one passing
through the intended anastomotic site into the LAD, and
the other passing up approximately 2 cm into the ITA adja-
cent to the anastomotic site (Fig 1). Two 7-0 Prolene stay
sutures (Ethicon) were placed laterally on either side of the
anastomosis to facilitate orientation of the balloons.
Balloons were inflated and BioGlue adhesive was applied
around the anastomosis and allowed to set for 2 minutes.
Additional BioGlue adhesive was placed on the heart to
assess its long-term reactivity. After 2 minutes, the catheter
balloons were deflated and the catheters were withdrawn.
Flow through the ITA was assured and then a Ligaclip was
applied to the distal end of the ITA graft, turning the anas-
tomosis from a side-to-side anastomosis to an end-to-side
anastomosis. The crossclamp was removed from the heart.
The hearts were defibrillated into a normal sinus rhythm
and the animals were weaned uneventfully from cardiopul-
monary bypass. Heparin was reversed with protamine sul-
fate and the chest was closed. An autopsy of 1 animal was
done 24 hours after the operation to assess early results;
two other animals were allowed to recover and autopsies
were done 10 months and 1 year after the procedure. The
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animals were fed a normal diet and received humane care
in compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources and published by the
National Institutes of Health (NIH publication 86-23,
revised 1985). All procedures were approved by the Animal
Experimentation Committee of Loma Linda University
School of Medicine.
Results
In vitro results. A total of 42 anastomoses were cre-
ated with the catheter system and BioGlue adhesive.
All anastomoses easily withstood an infusion of saline
solution at a pressure of 300 mm Hg, with the highest
pressure recorded at 560 mm Hg. All anastomoses had
patent proximal and distal coronary arteries as evi-
denced by saline solution leaking out the coronary ostia
and from the distal cut coronary artery. No leaks were
detected at the site of the BioGlue anastomosis with
infusion of saline solution. Macroscopically, no glue
was found intraluminally. No histologic sections were
performed.
In vivo results. All goat hearts were weaned
uneventfully from cardiopulmonary bypass. All three
hearts had regained normal contractility in the distribu-
tion of the distal LAD coronary artery with an open
ITA and the crossclamp still in place. In the first goat
heart, the proximal LAD was clipped with a Ligaclip.
The autopsy of the subsequent two goats found that the
Ligaclip had not completely gone over the proximal
LAD, resulting in patent LADs in both goats 2 and 3 at
10 months and 1 year after the operation. All goats
were fully heparinized before being put to death. After
death, the hearts were carefully dissected out, preserv-
ing the ITA pedicle. In goat 1, there was a patent ITA
graft to the LAD and minimal surrounding tissue reac-
tion. In goat 2, 10 months postoperatively, there were
minimal pericardial adhesions, and portions of the
BioGlue adhesive surrounding the anastomosis were
still present surrounded with a thin capsule. The anas-
tomotic site was completely patent, as was the proxi-
mal and distal LAD coronary artery. The mid right ITA
was occluded because of a technical error of kinking at
the graft coming over the pericardium. Goat 3 was put
to death 1 year after the operation. The left ITA was
completely patent, as was the anastomotic site. A coro-
nary angiogram was performed through the ITA, and
results are shown in Fig 2. These results demonstrated
a completely patent anastomosis with no areas of
stenosis, distortion, or aneurysm formation. As in goat
2, there were typical pericardial adhesions within the
pericardium and there were still areas of BioGlue adhe-
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Fig 1. Artist’s conception of the anastomosis created with
biologic glue. 1, The ITA is placed parallel to the LAD coro-
nary artery. Incisions made on the underside of the ITA and
the exposed surface of the LAD. 2, An angioplasty-type bal-
loon catheter is advanced through the arteriotomies and
inflated. A second catheter is advanced up the ITA and inflat-
ed to preserve luminal integrity. BioGlue adhesive is dis-
pensed over the anastomosis and allowed to set for 2 minutes.
3, Catheters are withdrawn, distal ITA flow is observed, and
the tip of the ITA is clipped to convert the side-to-side anas-
tomosis to an end-to-side anastomosis.
Fig 2.  Coronary angiogram of left ITA–LAD coronary artery
anastomosis taken 1 year after the operation. The anastomo-
sis was performed with the use of BioGlue adhesive and bal-
loon catheters as described in the text.
sive that had not been absorbed but were merely sur-
rounded by a capsule-like formation. BioGlue adhesive
could easily be peeled off the heart where it had been
placed 1 year previously. Histologic sections were
made, the results of which are shown in Fig 3. No
inflammatory reaction to the BioGlue adhesive was
found microscopically. The luminal margins were
smooth and also without reaction.
Discussion
These preliminary results demonstrate that a biologic
glue made from the combination of bovine albumin and
glutaraldehyde is effective in vitro in producing leak-
free sutureless coronary artery anastomoses capable of
withstanding very high distention pressures, higher cer-
tainly than any encountered within human blood pres-
sure ranges. Moreover, our in vivo studies in goats,
although small in number, suggest that this anastomo-
sis can be patent 1 full year after construction with
BioGlue adhesive. This finding is in contradistinction
to earlier attempts with glued or laser-welded anasto-
moses, which resulted in excessive rates of early
thrombosis and early or late suture-line disruption lead-
ing to aneurysm formation. Furthermore, this glue is
unlike gelatin-resorcin-formol glue, which uses glu-
taraldehyde, resorcinol, and fibrin to achieve less adhe-
sive qualities.3,5,6 If confirmed in a larger series of ani-
mals, this sutureless anastomosis created with the aid
of a biologic glue opens up tremendous avenues for
minimally invasive coronary artery bypass in human
beings. The advantages of a glued anastomosis versus a
sutured or stapled anastomosis revolve around the
potential of delivering the glue through extremely small
catheters and using equally small catheters to stabilize
the two vessels being anastomosed, as described in this
experimental model. With further modification of the
vessel-approximating catheters, truly minimally inva-
sive operations based on catheters and biologic glue
appear not only possible but feasible.
The lack of a significant inflammatory response and
the fact that the goats continued to grow for up to 1
year of follow-up suggest that any detrimental reactiv-
ity of the glue to the surrounding tissue is minimal.
Although it is unknown whether the same amount of
minimal reaction might be found in human beings, the
current clinical trials of the glue in aortic dissection
have shown no untoward reactions to the glue.
Therefore, it is likely that these animal results can be
extrapolated to human coronary artery anastomoses
quite easily. At the very least, the use of this glue as an
adjunct to other forms of rapid anastomosis, whether it
be with sutures, stapling, or laser, affords new consid-
eration of these techniques in combination with glue as
an alternative to standard anastomoses.1-6
Conclusion
In this brief report, we describe our first experience
with BioGlue adhesive (a combination with bovine
albumin and glutaraldehyde) as a method of creating a
coronary artery anastomosis in both in vitro and in vivo
experimental models. Further confirmation of these
results would suggest that trials of this glue be under-
taken in human beings as a method of achieving truly
minimally invasive coronary artery bypass with the
potential for long-term patency.
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Fig 3. Microscopic section at the junction of the ITA and
LAD coronary artery at site of BioGlue application. Note the
lack of inflammatory tissue and pieces of intact BioGlue
adhesive outside the anastomosis.
Discussion
Dr Juan C. Chachques (Paris, France). Did you do any
histologic studies at the level of the anastomosis? It would be
interesting to know what happened to the intima, because
some chemical products can induce inflammatory reactions. 
Dr Gundry. Those histologic specimens are still under
review. I waited a full year to do this last animal’s autopsy
(which I did last week), so I do not have histologic results.
Visually and using loupes we could find no intimal irregular-
ities, and there are no intimal irregularities on the angiogram.
However, the histologic information is pending. 
Dr James W. Frederiksen (Chicago, Ill). Have you consid-
ered using BioGlue surgical adhesive to control unsuturable
bleeding, for which fibrin sealant is currently recommended?
Dr Gundry. An investigational device exemption (IDE)
trial is underway in the United States for the use of BioGlue
adhesive in the treatment of acute aortic dissection. In those
cases, the investigators, including me, have used BioGlue
adhesive for either the prevention of what we believed would
be an uncontrollable leak or the subsequent treatment of a
leak uncontrollable by suture. Clinically, it works very well. 
Dr Verdi J. DiSesa (Chicago, Ill). You say that this adhe-
sive will stick even in the presence of blood? 
Dr Gundry. Yes, it will bind to anything. It will bind to the
blood actively, as well as to other tissue. And it will set up
under water, so the field does not have to be perfectly dry for
this substance to work. 
Dr Richard P. Cochran (Madison, Wis). Do you think the
double-balloon technique will limit the size of vessel that you
can use? As the vessels get smaller and smaller, inserting two
balloons may be very difficult. 
Dr Gundry. These balloons were actually modified 1- to
2-mm angioplasty balloon catheters. We used them initially
in yearling goats weighing about 40 kg, so the ITAs were
quite small. At autopsy, these animals weighed approximate-
ly 65 kg, so they grew with these anastomoses. This glue does
not seem to be detrimental to growth. In fact, the glue was
flexible at 1 year. 
Dr Alain F. Carpentier (Paris, France). It was not clear
from your drawing how you positioned the balloon. Could
you elaborate on this technical point?
Dr Gundry. The balloons were both placed through the
distal ITA. One balloon was placed in the ITA itself, because
earlier trials in vitro had shown that the ITA, if totally decom-
pressed or flattened, would stay in that position after the glue
was applied. We merely allowed the ITA to be distended by
the balloon to keep it from being compressed. 
The second balloon went through the anastomosis and was
present within the ITA and the LAD across the anastomosis
to seal the anastomosis from glue getting inside and to hold
the anastomosis steady. The glue was then applied outside,
and it was allowed to set up in 2 minutes. The glue gets about
60% of its holding power in 20 seconds and about 95% of its
holding power in 2 minutes, so it is a fairly rapid procedure. 
Dr Marko I. Turina (Zurich, Switzerland). Other investi-
gators using laser and similar methods found it is simpler to
use some stay sutures to support the anastomosis. Did you
find this to be the case?
I also have a comment concerning some previous studies
that were done, especially in the United Kingdom, with this
type of anastomosis, although using laser assistance rather
than this method. The fact emerged that early results might be
excellent, but there was a very high incidence of late
aneurysm at the anastomosis. I would respectfully submit that
it is advisable to use a large number of animals and very care-
fully check for anastomotic aneurysms.
Dr Gundry. I certainly agree with you. We actually used
two stay stitches on the outside of the vessels, on the lateral
walls, to pull the vessels apart. They were removed after the
glue was applied. All the in vitro anastomoses we did totally
without sutures. We found it more practical in the living ani-
mal to pull the vessel apart with two stay sutures, so those
were applied just to hold tissue apart.
Late aneurysm formation is a major problem, particularly
with laser-weld anastomoses. That is why I purposely waited
so long, 10 months and 1 year, to evaluate these anastomoses
for that possibility. Again, the series is extremely small and
obviously more experiments in animals have to be done.
However, the fact that the glue is still present around the
anastomosis at 1 year gives me some encouragement that the
late aneurysm formation with other techniques will not be
seen in this technique. 
Dr DiSesa. Is this is a thin bead of glue or a wad of glue? 
Dr Gundry. This is a wad of glue on the outside. It is not
purposefully put on the contact area between the two intimal
surfaces.
Dr. Mohamed Emara (Cairo, Egypt). How can you exactly
fix the size of the ITA and the native coronary artery with your
catheter? How can you be sure? And what is the proportion?
How much do you open on the ITA and the native artery? 
Dr Gundry. We choose a balloon catheter to match the size
of the LAD diameter. The balloon catheter actually holds
those two vessels apart through that anastomosis and that
determines the size of the anastomosis. In other words, if you
wanted a 3-mm anastomosis, you would use a 3-mm balloon
to spread it that far. If you wanted a 1-mm anastomosis, you
would use a 1-mm balloon. It is totally dependent on the bal-
loon size. 
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